Clinical studies in the pipeline: the therapies of tomorrow in tr...(anoma myeloma and a variety of sarcomas ...),Health

The researchers found that once a week administration of R1507 was well tolerated with very few side effects and none of those typically associated with cancer therapy, such as low blood counts, risk for infection, hair loss, severe nausea and vomiting. Although the vast majority of side effects were mild lower than what the researchers classified as grade 3 intensity there were two serious adverse events (stroke and high bilirubin, a breakdown in red blood cells) in patients while they were on treatment. But it is not certain that the adverse events were caused by the drug, Dr. Leong says. With a very small number of patients treated, the true and related side effects are still being evaluated, he said.

'/>"/>